{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T22:49:01Z","timestamp":1767134941496,"version":"build-2238731810"},"update-to":[{"DOI":"10.1002\/14651858.cd010271","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2014,2,15]],"date-time":"2014-02-15T00:00:00Z","timestamp":1392422400000}}],"reference-count":92,"publisher":"Wiley","issue":"2","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd010271.pub2","type":"journal-article","created":{"date-parts":[[2014,2,15]],"date-time":"2014-02-15T00:09:15Z","timestamp":1392422955000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["De-escalation treatment protocols for human papillomavirus-associated oropharyngeal squamous cell carcinoma"],"prefix":"10.1002","volume":"2014","author":[{"given":"Liam","family":"Masterson","sequence":"first","affiliation":[{"name":"Cambridge University Hospitals NHS Foundation Trust; ENT Department; Cambridge UK CB2 0QQ"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Moualed","sequence":"additional","affiliation":[{"name":"Great Western Hospitals NHS Foundation Trust; ENT Department; Swindon UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ajmal","family":"Masood","sequence":"additional","affiliation":[{"name":"Norfolk and Norwich University Hospital; ENT Department; Norwich UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raghav C","family":"Dwivedi","sequence":"additional","affiliation":[{"name":"Cambridge University Hospitals NHS Foundation Trust; ENT Department; Cambridge UK CB2 0QQ"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Benson","sequence":"additional","affiliation":[{"name":"Addenbrooke's Hospital; Oncology Centre; Box 193 Cambridge UK CB2 2QQ"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jane C","family":"Sterling","sequence":"additional","affiliation":[{"name":"Addenbrooke's Hospital; Department of Dermatology; Box 46 Cambridge UK CB2 2QQ"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kirsty M","family":"Rhodes","sequence":"additional","affiliation":[{"name":"University of Cambridge; MRC Biostatistics Unit; Newnham College Sidgwick Avenue Cambridge Cambridgeshire UK CB3 DF"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Holger","family":"Sudhoff","sequence":"additional","affiliation":[{"name":"Bielefeld Academic Teaching Hospital; Department of Otolaryngology, Head and Neck Surgery; Teutoburger Str. 50 Bielefeld Germany 33604"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Piyush","family":"Jani","sequence":"additional","affiliation":[{"name":"Cambridge University Hospitals NHS Foundation Trust; ENT Department; Cambridge UK CB2 0QQ"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Goon","sequence":"additional","affiliation":[{"name":"University of Cambridge; Department of Pathology; Cambridge UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2014,2,15]]},"reference":[{"issue":"10","key":"10.1002\/14651858.CD010271.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/j.oraloncology.2011.07.034","article-title":"Serum biomarkers as potential predictors of antitumor activity of cetuximab-containing therapy for locally advanced head and neck cancer","volume":"47","author":"Argiris","year":"2011","journal-title":"Oral Oncology"},{"issue":"1","key":"10.1002\/14651858.CD010271.pub2-BIB0002|cit2","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1002\/lary.23570","article-title":"Differential response rates to irradiation among patients with human papillomavirus positive and negative oropharyngeal cancer","volume":"123","author":"Chen","year":"2012","journal-title":"Laryngoscope"},{"key":"10.1002\/14651858.CD010271.pub2-BIB0003|cit3","unstructured":"Chera B Green R De-intensification of radiation and chemotherapy for low-risk human papillomavirus-related oropharyngeal squamous cell carcinoma http:\/\/clinicaltrials.gov\/ct2\/show\/record\/NCT01530997 2012"},{"key":"10.1002\/14651858.CD010271.pub2-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.radonc.2009.10.008","article-title":"HPV-associated p16-expression and response to hypoxic modification of radiotherapy in head and neck cancer","volume":"94","author":"Lassen","year":"2010","journal-title":"Radiotherapy and Oncology"},{"key":"10.1002\/14651858.CD010271.pub2-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.radonc.2011.02.010","article-title":"The influence of HPV-associated p16-expression on accelerated fractionated radiotherapy in head and neck cancer: evaluation of the randomised DAHANCA 6&7 trial","volume":"100","author":"Lassen","year":"2011","journal-title":"Radiotherapy and Oncology"},{"key":"10.1002\/14651858.CD010271.pub2-BIB0006|cit6","unstructured":"Eisbruch A Reduced-intensity therapy for advanced oropharyngeal cancer in non-smoking human papilloma virus (HPV)-16 positive patients http:\/\/clinicaltrials.gov\/show\/NCT01649414 2012"},{"issue":"4","key":"10.1002\/14651858.CD010271.pub2-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/jnci\/djn011","article-title":"Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial","volume":"100","author":"Fakhry","year":"2008","journal-title":"Journal of the National Cancer Institute"},{"issue":"4","key":"10.1002\/14651858.CD010271.pub2-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1002\/cncr.26364","article-title":"Phase 2 trial of oxaliplatin and pemetrexed as an induction regimen in locally advanced head and neck cancer","volume":"118","author":"Gilbert","year":"2012","journal-title":"Cancer"},{"key":"10.1002\/14651858.CD010271.pub2-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"S205","DOI":"10.1016\/j.ijrobp.2012.07.532","article-title":"Temporal regression of cervical lymph node in N2-N3 head-and-neck cancer treated with primary radiation therapy +\/- chemotherapy: stratified by HPV status","volume":"1","author":"Huang","year":"2012","journal-title":"International Journal of Radiation Oncology, Biology, Physics"},{"issue":"1","key":"10.1002\/14651858.CD010271.pub2-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1200\/JCO.2009.23.0425","article-title":"Induction chemotherapy and cetuximab for locally advanced squamous cell carcinoma of the head and neck: results from a phase II prospective trial","volume":"28","author":"Kies","year":"2010","journal-title":"Journal of Clinical Oncology"},{"issue":"6","key":"10.1002\/14651858.CD010271.pub2-BIB0011|cit11","doi-asserted-by":"publisher","first-page":"1798","DOI":"10.1158\/1078-0432.CCR-11-2094","article-title":"Prognostic and predictive significance of plasma HGF and IL-8 in a phase III trial of chemoradiation with or without tirapazamine in locoregionally advanced head and neck cancer","volume":"18","author":"Le","year":"2012","journal-title":"Clinical Cancer Research"},{"key":"10.1002\/14651858.CD010271.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"Abstract TPS560","DOI":"10.1200\/jco.2012.30.15_suppl.tps5601","article-title":"Phase II trial of neoadjuvant chemotherapy for HPV-associated squamous cell carcinoma of the oropharynx followed by reduced-dose radiotherapy\/chemoradiotherapy for responders or standard dose chemoradiotherapy for non-responders","volume":"30","author":"Mehrotra","year":"2012","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD010271.pub2-BIB0013|cit13","doi-asserted-by":"crossref","unstructured":"Merlano M Denaro N The phase III study interceptor in HNC: preliminary report on toxicity Oral Oncology 2013 S21 2","DOI":"10.1016\/j.oraloncology.2013.03.051"},{"issue":"1","key":"10.1002\/14651858.CD010271.pub2-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.radonc.2012.02.009","article-title":"Outcomes of HPV-related oropharyngeal cancer patients treated by radiotherapy alone using altered fractionation","volume":"103","author":"O'Sullivan","year":"2012","journal-title":"Radiotherapy and Oncology"},{"issue":"15 Suppl","key":"10.1002\/14651858.CD010271.pub2-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"Abstract e16032","DOI":"10.1200\/jco.2011.29.15_suppl.e16032","article-title":"P16 protein status and response to treatment in a prospective clinical trial (ECOG 2303) of patients with head and neck squamous cell carcinoma (HNSCC)","volume":"29","author":"Psyrri","year":"2011","journal-title":"Journal of Clinical Oncology"},{"issue":"3","key":"10.1002\/14651858.CD010271.pub2-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"S208","DOI":"10.1016\/j.ijrobp.2012.07.540","article-title":"Phase II study of radiation therapy dose de-intensification for HPV-associated oropharyngeal carcinoma","volume":"84","author":"Quon","year":"2012","journal-title":"International Journal of Radiation Oncology, Biology, Physics"},{"key":"10.1002\/14651858.CD010271.pub2-BIB0017|cit17","unstructured":"Jones T A phase I, dose escalation trial of recombinant listeria monocytogenes (Lm)- based vaccine encoding human papilloma virus serotype 16 target antigens (ADXS11-001) in patients with HPV-16 +ve oropharyngeal carcinoma Liverpool Cancer Trials Unit (http:\/\/www.lctu.org.uk\/trial\/trial_info.asp?id=73&tgcode=2&menuid=30)"},{"issue":"1","key":"10.1002\/14651858.CD010271.pub2-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1056\/NEJMoa0912217","article-title":"Human papillomavirus and survival of patients with oropharyngeal cancer","volume":"363","author":"Ang","year":"2010","journal-title":"New England Journal of Medicine"},{"issue":"15 Suppl","key":"10.1002\/14651858.CD010271.pub2-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"Abstract 5500","DOI":"10.1200\/jco.2011.29.15_suppl.5500","article-title":"A randomized phase III trial (RTOG 0522) of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III-IV head and neck squamous cell carcinomas","volume":"29","author":"Ang","year":"2011","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD010271.pub2-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1200\/JCO.2011.38.4099","article-title":"Tobacco smoking and increased risk of death and progression for patients with p16-positive and p16-negative oropharyngeal cancer","volume":"10","author":"Gillison","year":"2012","journal-title":"Journal of Clinical Oncology"},{"issue":"15 Suppl","key":"10.1002\/14651858.CD010271.pub2-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"Abstract 5519","DOI":"10.1200\/jco.2011.29.15_suppl.5519","article-title":"A randomized phase II trial of cetuximab-based induction chemotherapy followed by concurrent cetuximab, 5-FU, hydroxyurea, and hyperfractionated radiation (CetuxFHX), or cetuximab, cisplatin, and accelerated radiation with concomitant boost (CetuxPX) in patients with locoregionally advanced head and neck cancer (HNC)","volume":"29","author":"Seiwert","year":"2011","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD010271.pub2-BIB0022|cit22","unstructured":"Semrau R Duerbaum H Temming S Huebbers C Stenner M Drebber U Prognostic impact of human papillomavirus status, survivin, and epidermal growth-factor receptor expression on survival in patients treated with radiochemotherapy for very advanced nonresectable oropharyngeal cancer Head and Neck 10.1002\/hed.23126"},{"key":"10.1002\/14651858.CD010271.pub2-BIB0023|cit23","unstructured":"Siu L Waldron J Radiation therapy and cisplatin or panitumumab in treating patients with locally advanced stage III or stage IV head and neck cancer http:\/\/clinicaltrials.gov\/show\/NCT00820248 2009"},{"issue":"5","key":"10.1002\/14651858.CD010271.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1007\/s00405-010-1396-7","article-title":"Impact of HPV infection on the clinical outcome of p-CAIR trial in head and neck cancer","volume":"268","author":"Snietura","year":"2011","journal-title":"European Archives of Oto-Rhino-Laryngology"},{"key":"10.1002\/14651858.CD010271.pub2-BIB0025|cit25","unstructured":"Takenaka Y Phase II study of de-intensified treatment (radiation alone) for human papilloma virus-associated oropharyngeal cancer http:\/\/apps.who.int\/trialsearch\/trial.aspx?trialid=JPRN-UMIN000008953 2013"},{"issue":"5","key":"10.1002\/14651858.CD010271.pub2-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1093\/annonc\/mdr006","article-title":"Survival and human papillomavirus in oropharynx cancer in TAX 324: a subset analysis from an international phase III trial","volume":"22","author":"Posner","year":"2011","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD010271.pub2-BIB0027|cit27","unstructured":"Teknos T Vorinostat in the treatment of advanced staged oropharyngeal squamous cell carcinoma http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01064921 2010"},{"key":"10.1002\/14651858.CD010271.pub2-BIB0028|cit28","unstructured":"Thibaudeau E Fortin B Coutl\u00e9e F HPV prevalence and prognostic value in a prospective cohort of 255 patients with locally advanced HNSCC: a single-centre experience International Journal of Otolaryngology 10.1155\/2013\/437815"},{"issue":"27","key":"10.1002\/14651858.CD010271.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"4142","DOI":"10.1200\/JCO.2010.29.2904","article-title":"Prognostic significance of p16INK4A and human papillomavirus in patients with oropharyngeal cancer treated on TROG 02.02 phase III trial","volume":"28","author":"Rischin","year":"2010","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD010271.pub2-BIB0030|cit30","unstructured":"Yao M Erlotinib, docetaxel, and radiation therapy in stage III or stage IV squamous cell carcinoma of the head and neck http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00720304 2008"},{"key":"10.1002\/14651858.CD010271.pub2-BIB0031|cit31","unstructured":"Cohen E Selection of chemoradiotherapy based on response to induction chemotherapy - a randomized phase II study in locally advanced squamous cell carcinoma of head and neck http:\/\/clinicaltrials.gov\/show\/NCT01133678 2010"},{"key":"10.1002\/14651858.CD010271.pub2-BIB0032|cit32","unstructured":"Mehanna H De-ESCALaTE: Determination of epidermal growth factor receptor-inhibitor (cetuximab) versus standard chemotherapy (cisplatin) early and late toxicity events in human papillomavirus-positive oropharyngeal squamous cell carcinoma: a randomised controlled trial http:\/\/www.cancerresearchuk 2011"},{"key":"10.1002\/14651858.CD010271.pub2-BIB0033|cit33","unstructured":"Papadimitrakopoulou V Paclitaxel, carboplatin and cetuximab (PCC) versus cetuximab, docetaxel, cisplatin and fluorouracil (C-TPF) in previously untreated patients with locally advanced head and neck squamous cell carcinoma (HNSCC) http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01154920 2010"},{"key":"10.1002\/14651858.CD010271.pub2-BIB0034|cit34","unstructured":"Marur S Comis RL A phase II trial of induction chemotherapy followed by cetuximab (Erbitux) with low dose vs. standard dose IMRT in patients with HPV-associated resectable squamous cell carcinoma of the oropharynx http:\/\/clinicaltrials.gov\/show\/NCT01084083 2010"},{"key":"10.1002\/14651858.CD010271.pub2-BIB0035|cit35","unstructured":"Posner M The Quarterback Trial: a randomized phase III clinical trial comparing reduced and standard radiation therapy doses for locally advanced HPV16 positive oropharynx cancer http:\/\/clinicaltrials.gov\/show\/NCT01706939 2012"},{"key":"10.1002\/14651858.CD010271.pub2-BIB0036|cit36","unstructured":"Trotti A Phase III trial of radiotherapy plus cetuximab versus chemoradiotherapy in HPV-associated oropharynx cancer http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01302834 2011"},{"key":"10.1002\/14651858.CD010271.pub2-BIB0037|cit37","unstructured":"Rischin D Sivasuthan J A randomised trial of weekly cetuximab and radiation versus weekly cisplatin and radiation in good prognosis locoregionally advanced HPV-associated oropharyngeal squamous cell carcinoma http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01855451 2013"},{"issue":"1","key":"10.1002\/14651858.CD010271.pub2-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S1470-2045(09)70311-0","article-title":"Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival","volume":"11","author":"Bonner","year":"2010","journal-title":"Lancet Oncology"},{"issue":"9538","key":"10.1002\/14651858.CD010271.pub2-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/S0140-6736(06)69121-6","article-title":"Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis","volume":"368","author":"Bourhis","year":"2006","journal-title":"Lancet"},{"issue":"11","key":"10.1002\/14651858.CD010271.pub2-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1016\/j.ejca.2010.05.015","article-title":"Cetuximab in the management of locoregionally advanced head and neck cancer: expanding the treatment options?","volume":"46","author":"Bourhis","year":"2010","journal-title":"European Journal of Cancer"},{"issue":"32","key":"10.1002\/14651858.CD010271.pub2-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"4294","DOI":"10.1200\/JCO.2011.36.4596","article-title":"Human papillomavirus and rising oropharyngeal cancer incidence in the United States","volume":"29","author":"Chaturvedi","year":"2011","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD010271.pub2-BIB0042|cit42","first-page":"285","article-title":"Cancer of the oropharynx","volume-title":"Head and Neck Cancer: A Multidisciplinary Approach","author":"Choi","year":"2009"},{"issue":"2","key":"10.1002\/14651858.CD010271.pub2-BIB0043|cit43","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.ijrobp.2010.05.024","article-title":"Integrating epidermal growth factor receptor assay with clinical parameters improves risk classification for relapse and survival in head-and-neck squamous cell carcinoma","volume":"81","author":"Chung","year":"2011","journal-title":"International Journal of Radiation Oncology, Biology, Physics"},{"issue":"11","key":"10.1002\/14651858.CD010271.pub2-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/0003-4819-152-11-201006010-00232","article-title":"CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials","volume":"152","author":"Schulz","year":"2010","journal-title":"Annals of Internal Medicine"},{"key":"10.1002\/14651858.CD010271.pub2-BIB0045|cit45","volume-title":"Cancer Therapy Evaluation Program, Common Terminology Criteria for Adverse Events","author":"National Institutes of Health","year":"2009"},{"issue":"6","key":"10.1002\/14651858.CD010271.pub2-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/S1470-2045(12)70137-7","article-title":"Global burden of cancers attributable to infections in 2008: a review and synthetic analysis","volume":"13","author":"Martel","year":"2012","journal-title":"Lancet Oncology"},{"issue":"1","key":"10.1002\/14651858.CD010271.pub2-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1200\/JCO.2004.08.021","article-title":"Final results of the 94-01 French Head and Neck Oncology and Radiotherapy Group randomized trial comparing radiotherapy alone with concomitant radiochemotherapy in advanced-stage oropharynx carcinoma","volume":"22","author":"Denis","year":"2004","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD010271.pub2-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S1470-2045(09)70231-1","article-title":"Evidence-based organ-sparing radiotherapy in head and neck cancer","volume":"11","author":"Dirix","year":"2010","journal-title":"Lancet Oncology"},{"key":"10.1002\/14651858.CD010271.pub2-BIB0049|cit49","first-page":"192","article-title":"Tumours of the oropharynx","volume-title":"Principles and Practice of Head and Neck Surgery and Oncology","author":"Dwivedi","year":"2009"},{"issue":"9","key":"10.1002\/14651858.CD010271.pub2-BIB0050|cit50","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1002\/hed.23127","article-title":"Quality of life in head and neck cancer patients receiving multimodal or targeted therapy - update of the EORTC QLQ-H&N35, Phase I","volume":"35","author":"Singer","year":"2013","journal-title":"Head and Neck"},{"key":"10.1002\/14651858.CD010271.pub2-BIB0051|cit51","volume-title":"EQ-5D-3L User Guide","author":"Rabin","year":"2011"},{"issue":"7","key":"10.1002\/14651858.CD010271.pub2-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.clon.2010.05.024","article-title":"The changing aetiology of head and neck cancer: the role of human papillomavirus","volume":"22","author":"Evans","year":"2010","journal-title":"Clinical Oncology"},{"issue":"6","key":"10.1002\/14651858.CD010271.pub2-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1053\/j.seminoncol.2004.09.011","article-title":"Human papillomavirus-associated head and neck cancer is a distinct epidemiologic, clinical, and molecular entity","volume":"31","author":"Gillison","year":"2004","journal-title":"Seminars in Oncology"},{"key":"10.1002\/14651858.CD010271.pub2-BIB0054|cit54","first-page":"12513-8","article-title":"Repression of human papillomavirus oncogenes in HeLa cervical carcinoma cells causes the orderly reactivation of dormant tumor suppressor pathways","volume":"97","author":"Goodwin","year":"2000","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1002\/14651858.CD010271.pub2-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1634\/theoncologist.12-5-555","article-title":"Intensity-modulated radiation therapy for head and neck carcinoma","volume":"12","author":"Gr\u00e9goire","year":"2007","journal-title":"Oncologist"},{"key":"10.1002\/14651858.CD010271.pub2-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1093\/annonc\/mdq185","article-title":"Squamous cell carcinoma of the head and neck: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"21","author":"Gregoire","year":"2010","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD010271.pub2-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1056\/NEJMra0707975","article-title":"Recent advances in head and neck cancer","volume":"359","author":"Haddad","year":"2008","journal-title":"New England Journal of Medicine"},{"issue":"3","key":"10.1002\/14651858.CD010271.pub2-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S1470-2045(13)70011-1","article-title":"Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial","volume":"14","author":"Haddad","year":"2013","journal-title":"Lancet Oncology"},{"key":"10.1002\/14651858.CD010271.pub2-BIB0059|cit59","unstructured":"Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"issue":"34","key":"10.1002\/14651858.CD010271.pub2-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"8636","DOI":"10.1200\/JCO.2004.00.1990","article-title":"Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer","volume":"23","author":"Hitt","year":"2005","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD010271.pub2-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"1595-602","DOI":"10.1002\/ijc.25174","article-title":"p16(INK4a) overexpression predicts translational active human papillomavirus infection in tonsillar cancer","volume":"127","author":"Hoffmann","year":"2010","journal-title":"International Journal of Cancer"},{"issue":"11","key":"10.1002\/14651858.CD010271.pub2-BIB0062|cit62","doi-asserted-by":"publisher","first-page":"2088","DOI":"10.1016\/j.ejca.2010.04.016","article-title":"Relationships between epidermal growth factor receptor expression and human papillomavirus status as markers of prognosis in oropharyngeal cancer","volume":"46","author":"Hong","year":"2010","journal-title":"European Journal of Cancer"},{"issue":"19","key":"10.1002\/14651858.CD010271.pub2-BIB0063|cit63","doi-asserted-by":"publisher","first-page":"3128","DOI":"10.1200\/JCO.2007.12.7662","article-title":"EGFR, p16, HPV Titer, Bcl-xL and p53, sex, and smoking as indicators of response to therapy and survival in oropharyngeal cancer","volume":"26","author":"Kumar","year":"2008","journal-title":"Journal of Clinical Oncology"},{"issue":"5","key":"10.1002\/14651858.CD010271.pub2-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.tripleo.2011.06.032","article-title":"Prevalence and impact of complications on outcomes in patients hospitalized for oral and oropharyngeal cancer treatment","volume":"112","author":"Lee","year":"2011","journal-title":"Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology and Endodontics"},{"issue":"7","key":"10.1002\/14651858.CD010271.pub2-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1200\/JCO.2012.42.3988","article-title":"Induction chemotherapy followed by either chemoradiotherapy or bioradiotherapy for larynx preservation: the TREMPLIN randomized phase II study","volume":"31","author":"Lefebvre","year":"2013","journal-title":"Journal of Clinical Oncology"},{"issue":"36","key":"10.1002\/14651858.CD010271.pub2-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"5630","DOI":"10.1200\/JCO.2005.04.6136","article-title":"High-risk human papillomavirus affects prognosis in patients with surgically treated oropharyngeal squamous cell carcinoma","volume":"24","author":"Licitra","year":"2006","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD010271.pub2-BIB0067|cit67","first-page":"137","article-title":"Oropharyngeal cancer","volume-title":"Head and Neck Cancer","author":"Mehanna","year":"2011"},{"key":"10.1002\/14651858.CD010271.pub2-BIB0068|cit68","unstructured":"Mehanna H Beech T Nicholson T El-Hariry I McConkey C Paleri V The prevalence of human papillomavirus in oropharyngeal and nonoropharyngeal head and neck cancer: a systematic review and meta-analysis of trends by time and region Head and Neck 10.1002\/hed.22015"},{"key":"10.1002\/14651858.CD010271.pub2-BIB0069|cit69","first-page":"729","article-title":"Treatment of head and neck cancer","volume-title":"Cancer: Principles and Practice of Oncology","author":"Mendenhall","year":"2011"},{"issue":"10","key":"10.1002\/14651858.CD010271.pub2-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1097\/CAD.0b013e3283330590","article-title":"Epidermal growth factor receptor inhibitors in cancer treatment: advances, challenges and opportunities","volume":"20","author":"Modjtahedi","year":"2009","journal-title":"Anticancer Drugs"},{"issue":"1","key":"10.1002\/14651858.CD010271.pub2-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.semradonc.2008.09.007","article-title":"Dysphagia in head and neck cancer patients treated with radiation: assessment, sequelae, and rehabilitation","volume":"19","author":"Murphy","year":"2009","journal-title":"Seminars in Radiation Oncology"},{"key":"10.1002\/14651858.CD010271.pub2-BIB0072|cit72","unstructured":"National Comprehensive Cancer Network NCCN Guidelines for Treatment of Cancer by Site (Head & Neck Cancer) http:\/\/www.nccn.org\/professionals\/physician_gls\/f_guidelines.asp 2010"},{"key":"10.1002\/14651858.CD010271.pub2-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"675-80","DOI":"10.1259\/bjr\/72852974","article-title":"Analysis of factors influencing aspiration risk following chemoradiation for oropharyngeal cancer","volume":"82","author":"Nguyen","year":"2009","journal-title":"British Journal of Radiology"},{"issue":"2","key":"10.1002\/14651858.CD010271.pub2-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S1470-2045(10)70290-4","article-title":"Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial","volume":"12","author":"Nutting","year":"2011","journal-title":"Lancet Oncology"},{"key":"10.1002\/14651858.CD010271.pub2-BIB0075|cit75","first-page":"607-14","article-title":"The IARC TP53 database: new online mutation analysis and recommendations to users","volume":"19","author":"Oliver","year":"2002","journal-title":"Human Mutation"},{"key":"10.1002\/14651858.CD010271.pub2-BIB0076|cit76","unstructured":"Pajares B Perez-Villa L Trigo JM Toledo MD Alvarez M Jimenez B Concurrent radiotherapy plus epidermal growth factor receptor inhibitors in patients with human papillomavirus-related head and neck cancer Clinical & Translational Oncology"},{"issue":"24","key":"10.1002\/14651858.CD010271.pub2-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1002\/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8","article-title":"Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints","volume":"17","author":"Parmar","year":"1998","journal-title":"Statistics in Medicine"},{"key":"10.1002\/14651858.CD010271.pub2-BIB0078|cit78","unstructured":"Petrelli F Sarti E Barni S Predictive value of HPV in oropharyngeal carcinoma treated with radiotherapy: an updated systematic review and meta-analysis of 30 trials Head and Neck 10.1002\/hed.23351"},{"key":"10.1002\/14651858.CD010271.pub2-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.radonc.2009.04.014","article-title":"Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomized trials and 17,346 patients","volume":"92","author":"Pignon","year":"2009","journal-title":"Radiotherapy and Oncology"},{"issue":"17","key":"10.1002\/14651858.CD010271.pub2-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1056\/NEJMoa070956","article-title":"Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer","volume":"357","author":"Posner","year":"2007","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD010271.pub2-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1002\/ijc.22851","article-title":"Survival of squamous cell carcinoma of the head and neck in relation to human papillomavirus infection: review and meta-analysis","volume":"121","author":"Ragin","year":"2007","journal-title":"International Journal of Cancer"},{"key":"10.1002\/14651858.CD010271.pub2-BIB0082|cit82","unstructured":"The Nordic Cochrane Centre, The Cochrane Collaboration Review Manager (RevMan) 2012"},{"key":"10.1002\/14651858.CD010271.pub2-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"6262","DOI":"10.1158\/1078-0432.CCR-11-0388","article-title":"Evaluation of human papilloma virus diagnostic testing in oropharyngeal squamous cell carcinoma: sensitivity, specificity, and prognostic discrimination","volume":"17","author":"Schache","year":"2011","journal-title":"Clinical Cancer Research"},{"key":"10.1002\/14651858.CD010271.pub2-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"1541-7","DOI":"10.1007\/s00405-011-1714-8","article-title":"Evidence for a causal association for HPV in head and neck cancers","volume":"268","author":"Sudhoff","year":"2011","journal-title":"European Archives of Oto-Rhino-Laryngology"},{"key":"10.1002\/14651858.CD010271.pub2-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1745-6215-8-16","article-title":"Practical methods for incorporating summary time-to-event data into meta-analysis","volume":"8","author":"Tierney","year":"2007","journal-title":"Trials"},{"key":"10.1002\/14651858.CD010271.pub2-BIB0086|cit86","first-page":"232-5","article-title":"Biological evidence that human papillomaviruses are etiologically involved in a subgroup of head and neck squamous cell carcinomas","volume":"93","author":"Houten","year":"2001","journal-title":"International Journal of Cancer"},{"issue":"11","key":"10.1002\/14651858.CD010271.pub2-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa0802656","article-title":"Platinum-based chemotherapy plus cetuximab in head and neck cancer","volume":"359","author":"Vermorken","year":"2008","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.1002\/14651858.CD010271.pub2-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1002\/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F","article-title":"Human papillomavirus is a necessary cause of invasive cervical cancer worldwide","volume":"189","author":"Walboomers","year":"2009","journal-title":"Journal of Pathology"},{"key":"10.1002\/14651858.CD010271.pub2-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"5762-71","DOI":"10.1093\/emboj\/19.21.5762","article-title":"Papillomavirus E2 induces senescence in HPV-positive cells via pRB and p21(CIP) dependent pathways","volume":"19","author":"Wells","year":"2000","journal-title":"EMBO Journal"},{"key":"10.1002\/14651858.CD010271.pub2-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"78-81","DOI":"10.1007\/s12105-009-0100-y","article-title":"The changing face of head and neck cancer in the 21st century: the impact of HPV on the epidemiology and pathology of oral cancer","volume":"3","author":"Westra","year":"2009","journal-title":"Head and Neck Pathology"},{"key":"10.1002\/14651858.CD010271.pub2-BIB0091|cit91","volume-title":"International Classification of Diseases for Oncology (ICD-O)","author":"WHO","year":"2000"},{"key":"10.1002\/14651858.CD010271.pub2-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"1510-7","DOI":"10.1038\/sj.onc.1205214","article-title":"Involvement of intact HPV16 E6\/E7 gene expression in head and neck cancers with unaltered p53 status and perturbed pRb cell cycle control","volume":"21","author":"Wiest","year":"2002","journal-title":"Oncogene"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD010271.pub2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,17]],"date-time":"2023-11-17T03:34:29Z","timestamp":1700192069000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD010271.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane ENT Group","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2014,2,15]]},"references-count":92,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2014,2]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd010271.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,2,15]]}}}